C10orf27 Inhibitors
The efficacy of C10orf27 inhibitors is contingent upon the manipulation of intricate cellular pathways in which C10orf27 plays a critical role. By targeting these signaling cascades, these inhibitors can indirectly decrease the functional activity of C10orf27. For instance, the intervention in the PI3K/AKT/mTOR and MAPK/ERK pathways, which are crucial for cellular growth, proliferation, and response to stress, results in the downregulation of C10orf27, which is regulated by these pathways. The inhibition of upstream kinases such as MEK and JNK similarly leads to a reduction in the stability and function of C10orf27 due to the protein's association with these signaling routes. Additionally, compounds that disrupt protein neddylation or proteasome function can indirectly reduce C10orf27 activity through the modulation of protein turnover, as this protein's levels are sensitive to changes in such ubiquitin-proteasome system processes.
Further, inhibitors targeting energy homeostasis and calcium/calmodulin-dependent signaling exert an indirect impact on C10orf27 activity. Agents that inhibit kinases involved in cellular energy regulation, such as NUAK family kinases and AMPK, can result in altered C10orf27 function, given the protein's connection to metabolic control. Meanwhile, calmodulin antagonists that impede the related intracellular signaling pathways can similarly influence the activity of C10orf27.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor that suppresses cell growth and proliferation, indirectly reducing the cellular levels of C10orf27 due to its role in these processes. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A PI3K inhibitor that impairs the PI3K/AKT/mTOR pathway, thereby decreasing the stability and function of C10orf27 in the signal transduction. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A p38 MAPK inhibitor that impedes the inflammatory response, indirectly influencing C10orf27 activity involved in this pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
An ERK pathway inhibitor that disrupts the MAPK/ERK signaling, leading to downregulation of proteins including C10orf27 that are regulated by this pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
A JNK inhibitor that attenuates the stress-activated protein kinase pathway, indirectly diminishing the functional role of C10orf27 within this cascade. | ||||||
WZ4003 | 1214265-58-3 | sc-473979 | 5 mg | $300.00 | ||
A NUAK family kinase inhibitor that impedes cellular energy homeostasis, indirectly influencing C10orf27 activity tied to metabolic regulation. | ||||||
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $280.00 | 1 | |
A NEDD8-activating enzyme inhibitor that disrupts protein neddylation, affecting the degradation of proteins including C10orf27. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
A proteasome inhibitor that leads to the accumulation of polyubiquitinated proteins, indirectly reducing the activity of C10orf27 by affecting protein turnover. | ||||||
STO-609 | 52029-86-4 | sc-507444 | 5 mg | $140.00 | ||
A CaMKK inhibitor that affects calcium/calmodulin-dependent processes, decreasing the activity of C10orf27 by altering intracellular signaling. | ||||||
W-7 | 61714-27-0 | sc-201501 sc-201501A sc-201501B | 50 mg 100 mg 1 g | $163.00 $300.00 $1642.00 | 18 | |
A calmodulin antagonist that hinders calmodulin-dependent pathways, thereby decreasing the activity of C10orf27 connected to these pathways. | ||||||